Ranibizumab
Human-like monoclonal antibody (IgG1 immunoglobulin) produced by DNA recombinant technology. Action is by blockage of endothelial growth factor. Has been used for treatment of several types of cancer. Useful for treatment of eye macular degeneration secondary to choroidal neovascularization.
Because of a high molecular weight and a protein structure, excretion into breast milk and absorption by infant's gut are highly unlikely.
Intravitreal injection: because small doses used and low level observed in the plasma and because neither trace in breast milk nor side-effects in the infant have been reported, treatment is likely safe while breastfeeding.
It has advantage over Bevacizumab because it does not inhibit Vascular Endothelial Growth Factor (VEGF) that is present in the breast milk.
No harmful effects on infants from treated mothers have been reported.
Alternatives
We do not have alternatives for Ranibizumab since it is relatively safe.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- رانيبيزوماب (Arabic)
- Ранибицумаб (Cyrillic)
- 雷珠单抗 (Chinese)
- ラニビズマブ (Japanese)
Drug trade names
References
- Ehlken C, Martin G, Stahl A, Agostini HT. Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Arch Ophthalmol. 2012Abstract Full text (link to original source) Full text (in our servers)